|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||($31)||Benefits minus costs||($1,039)|
|Participants||($38)||Benefit to cost ratio||($0.86)|
|Others||($16)||Chance the program will produce|
|Indirect||($396)||benefits greater than the costs||49 %|
|Net program cost||($559)|
|Benefits minus cost||($1,039)|
|Detailed Monetary Benefit Estimates Per Participant|
|Benefits from changes to:1||Benefits to:|
|Labor market earnings associated with opioid drug abuse or dependence||($10)||($24)||$0||$0||($34)|
|Health care associated with opioid drug abuse or dependence||($16)||($2)||($16)||($8)||($42)|
|Mortality associated with opioids||($5)||($11)||$0||($109)||($125)|
|Adjustment for deadweight cost of program||$0||$0||$0||($279)||($279)|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$1,223||2016||Present value of net program costs (in 2018 dollars)||($559)|
|Comparison costs||$685||2016||Cost range (+ or -)||20 %|
|Estimated Cumulative Net Benefits Over Time (Non-Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in non-discounted dollars to simplify the “break-even” point from a budgeting perspective. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
|Meta-Analysis of Program Effects|
|Outcomes measured||Treatment age||No. of effect sizes||Treatment N||Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
|Opioid use disorder||36||4||169||0.006||0.109||36||0.000||0.187||39||0.006||0.956|
Fiellin, D.A., Barry, D.T., Sullivan, L.E., Cutter, C.J., Moore, B.A., O'Connor, P.G., & Schottenfeld, R.S. (2013). A randomized trial of Cognitive Behavioral Therapy in primary care-based buprenorphine. The American Journal of Medicine, 126(1).
Ling, W., Hillhouse, M., Ang, A., Jenkins, J., & Fahey, J. (2013). Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction, 108(10), 1788-1798.
Moore, B.A., Barry, D.T., Sullivan, L.E., O’Connor, P.G., Cutter, C.J., Schottenfeld, R.S., & Fiellin, D.A. (2012). Counseling and directly observed medication for primary care buprenorphine/naloxone maintenance. Journal of Addiction Medicine, 1.
Moore, B.A., Fazzino, T., Barry, D.T., Fiellin, D.A., Cutter, C.J., Schottenfeld, R.S., & Ball, S.A. (2013). The recovery line: A pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance. Journal of Substance Abuse Treatment, 45(1), 63-69.